Anti-HER2 monoclonal antibody （Sc7301）-paclitaxel （TAX） immunoconjugate was pre- pared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester metho...Anti-HER2 monoclonal antibody （Sc7301）-paclitaxel （TAX） immunoconjugate was pre- pared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester method and then the TAX-Sc7301 immunoconjugate was obtained. After purification and labeling by Cyano-fluorescein isothiocyanate （FITC）, the specific binding of TAX-Sc7301 to HER2-positive tumor cells （SKOV3） and HER2-negative tumor cells （HepG2） was evaluated respectively. TAX-Sc7301 （20 nmol/L） showed distinct specific binding to SKOV3 cells rather than HepG2 cells. And the uptake of the immunoconjugate by SKOV3 cells was increased with the TAX-So7301 concentration （3-48 nmol/L） and the incubation time （P〈0.05）. It was concluded that the TAX-Sc7301 immunoconjugate is ootentially applicable as a targeted agent against HER2-10ositive tumor cells.展开更多
基金supported by a grant from the National Natural Science Foundation of China(No.30300429)
文摘Anti-HER2 monoclonal antibody （Sc7301）-paclitaxel （TAX） immunoconjugate was pre- pared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester method and then the TAX-Sc7301 immunoconjugate was obtained. After purification and labeling by Cyano-fluorescein isothiocyanate （FITC）, the specific binding of TAX-Sc7301 to HER2-positive tumor cells （SKOV3） and HER2-negative tumor cells （HepG2） was evaluated respectively. TAX-Sc7301 （20 nmol/L） showed distinct specific binding to SKOV3 cells rather than HepG2 cells. And the uptake of the immunoconjugate by SKOV3 cells was increased with the TAX-So7301 concentration （3-48 nmol/L） and the incubation time （P〈0.05）. It was concluded that the TAX-Sc7301 immunoconjugate is ootentially applicable as a targeted agent against HER2-10ositive tumor cells.
